Green Valley Pharmaceuticals
Shanghai, China· Est.
A neuroscience-focused pharma company, known for developing GV-971, a novel oral drug for Alzheimer's disease.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
A neuroscience-focused pharma company, known for developing GV-971, a novel oral drug for Alzheimer's disease.
Neuroscience
Technology Platform
A novel drug discovery platform focused on the gut-brain axis and neuroinflammation for treating neurodegenerative diseases.
Opportunities
Enormous global market for Alzheimer's disease if international Phase 3 trials successfully confirm GV-971's clinical benefits.
Risk Factors
Risk that international Phase 3 trials may not confirm the efficacy seen in the China study, potentially limiting global adoption.
Competitive Landscape
Now competes with newly approved disease-modifying Alzheimer's therapies (e.g., Leqembi) and faces intense scientific scrutiny of its novel mechanism.